NCT02556086 - A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1) | Biotech Hunter

Timeline

Start Date

December 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

July 31, 2017

Conditions

Hepatitis C

Interventions

DRUG

Daclatasvir

DRUG

Sofosbuvir

Trial Locations (17)

13009

Local Institution, Marseille

33604

Local Institution, Pessac

44093

Local Institution, Nantes

75010

Local Institution, Paris

75015

Local Institution, Paris

75020

Local Institution, Paris

75679

Local Institution, Paris

75877

Local Institution, Paris

T6G 2B7

Local Institution, Edmonton

V6Z 2C7

Local Institution, Vancouver

V8V 3P9

Local Institution, Victoria

K1H 8L6

Local Institution, Ottawa

M5G 2N2

Local Institution, Toronto

H4A 3J1

Local Institution, Montreal

G1V 4G2

Local Institution, Québec

S4P 0W5

Local Institution, Regina

06202

Local Institution, Nice